Company profile: Helix
1.1 - Company Overview
Company description
- Provider of population genomics solutions to advance research and integrate genomic data into clinical care, offering Exome+® sequencing; an integrated platform to collect, sequence, interpret, store, and share genetic information with a DNA product marketplace; Helix Insights; population genomics programs; diagnostic testing for hereditary cancer, cardiovascular disorders, pharmacogenomics, and proactive screening; and large-scale research programs.
Products and services
- Helix Platform: Integrated platform that collects, sequences, interprets, stores, and shares genetic information, featuring a marketplace for DNA products to support clinical care and research
- Exome+®: Proprietary sequencing-based testing service that sequences the exome and additional non-coding regions, delivering comprehensive genetic insights for clinical and research applications
- Diagnostic Testing: Genetic tests for hereditary cancer, cardiovascular disorders, pharmacogenomics, and proactive health screening to integrate genomic data into clinical care
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Helix
SeQure Dx
HQ: United States
Website
- Description: Provider of safety data and diagnostic platforms for on- and off-target CRISPR gene editing therapies. Offers NoteSeQ (ONE-seq) for profiling off-target sites, ScopeSeQ for validating candidate edits via next-generation sequencing, risk assessment across the development lifecycle, discovery/IND support, clinical trial patient risk management, and post-approval diagnostic management with patient and physician education.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SeQure Dx company profile →
GenEdit
HQ: United States
Website
- Description: Provider of a proprietary non-viral, non-lipid polymer nanoparticle platform (NanoGalaxy) for safe, efficient delivery of genetic medicine payloads—including nucleic acids, therapeutic proteins, and CRISPR/Cas9—to specific tissues. Offers tissue selectivity, payload flexibility, ability to redose without immune response, and scalable manufacturing with batch-to-batch purity and long-term stability that reduces cold-chain logistics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GenEdit company profile →
Syngenta
HQ: Switzerland
Website
- Description: Provider of agricultural technologies and solutions that improve yields, crop resilience, and resource conservation. Offers crop protection from sowing to harvest; seeds and traits for grains, oilseeds, vegetables, fruits, and flowers; TYMIRIUM technology against nematodes and soil-borne pathogens; PERGADO Ultra fungicide for cocoa; and Shoots by Syngenta, a collaborative platform advancing sustainable agriculture.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Syngenta company profile →
Neogen
HQ: United States
Website
- Description: Provider of food and animal safety products, developing, manufacturing and marketing a diverse line dedicated to food and animal safety.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neogen company profile →
MyOme
HQ: United States
Website
- Description: Provider of a comprehensive genetic testing platform, MyOme Personal Genome, using whole genome sequencing to deliver insights into disease risk, medication response, and other health information. Offers Personal Genome reports identifying potential gene mutations and medication responses, and is developing Integrated Personal Risk Score Reports that combine genetic analysis with clinical risk factors for conditions like coronary artery disease and breast cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MyOme company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Helix
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Helix
2.2 - Growth funds investing in similar companies to Helix
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Helix
4.2 - Public trading comparable groups for Helix
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →